Status:
TERMINATED
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
Lead Sponsor:
Solvay Pharmaceuticals
Collaborating Sponsors:
H. Lundbeck A/S
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
Eligibility Criteria
Inclusion
- Diagnosis of Schizophrenia
- 18-65 years
- No hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period
Exclusion
- Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
- At significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00396214
Start Date
April 1 2007
End Date
January 1 2008
Last Update
June 4 2008
Active Locations (151)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 313
Anaheim, California, United States
2
Site 333
Anaheim, California, United States
3
Site 323
Cerritos, California, United States
4
Site 374
Costa Mesa, California, United States